Published Date: 13 Mar 2023
Researchers have found in a new study that exposure to ozone pollution can increase the number of hospitalizations associated with heart disease. Also...
Read Full NewsIn a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?
New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.
A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.
A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.
1.
Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.
2.
Vaccine elicits strong immune response in patients with pancreatic and colorectal cancer
3.
Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.
4.
Childhood brain tumors develop early in highly specialized nerve cells, research reveals
5.
Decoding calcifications in breast cancer: Towards personalized medicine
1.
Bispecific Antibodies in DLBCL & Myeloma: Clinical Insights for Physicians
2.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
3.
Unlocking the Potential of Cancer Antigen 19-9 for Early Detection
4.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
5.
New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
4.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
5.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation